AMGN
Amgen Inc.
269.06
USD
This page is just a preview of the data found in TrendSpider’s full version
Amgen Inc. stock is up 0.65% since 30 days ago. The next earnings date is Jan 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.41% of the previous 40 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 05 Dec 17:24 | 17 Jan, 2025 | 260.00 | 311 | ||
| 05 Dec 17:51 | 19 Jan, 2024 | 205.00 | 581 | ||
| 05 Dec 20:08 | 17 Jan, 2025 | 260.00 | 311 | ||
| 06 Dec 17:25 | 21 Jun, 2024 | 280.00 | 333 | ||
| 07 Dec 18:59 | 21 Jun, 2024 | 250.00 | 602 | ||
| 07 Dec 19:54 | 21 Jun, 2024 | 250.00 | 748 | ||
| 07 Dec 20:22 | 16 Feb, 2024 | 285.00 | 319 | ||
| 07 Dec 20:35 | 16 Feb, 2024 | 280.00 | 544 | ||
| 07 Dec 20:39 | 19 Jan, 2024 | 150.00 | 10 | ||
| 08 Dec 19:59 | 19 Jan, 2024 | 270.00 | 1122 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.
